In animal models of high fat diet (HFD)-induced insulin resistance, which is a hallmark of T2DM pathophysiology, TRAIL genetic deficiency was found to exacerbate insulin resistance and aspects of non-alcoholic fatty liver disease (NAFLD) such as hepatic steatosis, inflammation and fibrosis, generating the hypothesis that increasing TRAIL levels might represent an appealing therapeutic approach to improve glucose metabolism and liver histology in diabetic patients [16]. The gene discussed is TNFSF10; the disease is Insulin resistance.